Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer’s disease: A multicenter assessment

  • K. Blennow
  • G. De Meyer
  • O. Hansson
  • L. Minthon
  • A. Wallin
  • H. Zetterberg
  • P. Lewczuk
  • H. Vanderstichele
  • E. Vanmechelen
  • J. Kornhuber
  • J. Wiltfang
  • Knd-Study Group
JNHA: Clinical Trials and Aging

DOI: 10.1007/s12603-009-0059-0

Cite this article as:
Blennow, K., De Meyer, G., Hansson, O. et al. J Nutr Health Aging (2009) 13: 205. doi:10.1007/s12603-009-0059-0

Abstract

Objective

To better understand the seemingly contradictory plasma β-amyloid (Aβ) results in Alzheimer’s disease (AD) patients by using a newly developed plasma Aβ assay, the INNO-BIA plasma Aβ forms, in a multicenter study.

Methods

A combined retrospective analysis of plasma Aβ isoforms on mild cognitive impairment (MCI) from three large cross-sectional studies involving 643 samples from the participating German and Swedish centers.

Results

Detection modules based on two different amino (N)-terminal specific Aβ monoclonal antibodies demonstrated that Aβ in plasma could be reliable quantified using a sandwich immunoassay technology with high precision, even for low Aβ42 plasma concentrations. Aβ40 and Aβ42 concentrations varied consistently with the ApoE genotype, while the Aβ42/Aβ40 ratio did not. Irrespective of the decrease of the Aβ42/Aβ40 ratio with age and MMSE, this parameter was strongly associated with AD, as defined in this study by elevated hyperphosphorylated (P-tau181P) levels in cerebrospinal fluid (CSF).

Conclusion

A highly robust assay for repeatedly measuring Aβ forms in plasma such as INNO-BIA plasma Aβ forms might be a useful tool in a future risk assessment of AD.

Copyright information

© Serdi and Springer Verlag France 2009

Authors and Affiliations

  • K. Blennow
    • 1
  • G. De Meyer
    • 2
  • O. Hansson
    • 3
    • 4
  • L. Minthon
    • 3
    • 4
  • A. Wallin
    • 1
  • H. Zetterberg
    • 1
  • P. Lewczuk
    • 5
  • H. Vanderstichele
    • 2
  • E. Vanmechelen
    • 2
  • J. Kornhuber
    • 5
  • J. Wiltfang
    • 6
  • Knd-Study Group
  1. 1.Sahlgrenska University HospitalGöteborg UniversityGöteborgSweden
  2. 2.InnogeneticsGentBelgium
  3. 3.Department of Clinical SciencesClinical Memory Research UnitMalmöSweden
  4. 4.Department of PsychiatryLund UniversityLundSweden
  5. 5.Department of PsychiatryUniversity Hospital ErlangenErlangenGermany
  6. 6.Kliniken/Institut der Universität Duisburg-EssenEssenGermany

Personalised recommendations